Emerald Mutual Fund Advisers Trust’s Spyre Therapeutics SYRE Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.6M	Sell	401,271 -6,842	-2%	-$499K	1.25%	24
2026 Q1	$20.6M	Sell	408,113 -4,258	-1%	-$161K	1%	30
2025 Q4	$13.5M	Buy	412,371 +104,159	+34%	+$2.72M	0.66%	68
2025 Q3	$5.17M	Sell	308,212 -21,218	-6%	-$346K	0.27%	104
2025 Q2	$4.93M	Sell	329,430 -59,992	-15%	-$888K	0.3%	102
2025 Q1	$6.28M	Buy	389,422 +3,038	+0.8%	+$63.2K	0.45%	81
2024 Q4	$9M	Buy	386,384 +132,834	+52%	+$3.9M	0.55%	72
2024 Q3	$7.46M	Buy	+253,550	New	+$7.06M	0.39%	85

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's SYRE Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its Spyre Therapeutics (SYRE) stake by 1.7% in Q2 2026, selling an estimated $499K and leaving 401,271 shares worth $35.6M. The position accounts for 1.25% of the portfolio, ranked #24.

Emerald Mutual Fund Advisers Trust first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Emerald Mutual Fund Advisers Trust held 401,271 shares of Spyre Therapeutics worth $35.6M as of Q2 2026.
Emerald Mutual Fund Advisers Trust sold 6,842 Spyre Therapeutics shares in Q2 2026, an estimated $499K.
Spyre Therapeutics made up 1.25% of Emerald Mutual Fund Advisers Trust's portfolio in Q2 2026, its #24 holding.
Emerald Mutual Fund Advisers Trust first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.